Dear members of the Korean Peptide and Protein Society,

Greetings. I am Jeong Kyu Bang, President of the Korean Peptide and Protein Society.

I would like to express my sincere gratitude to all our members for your continued interest and support for the growth and advancement of our Society.

In recent years, the peptide drug field has made remarkable progress, driven by the advancement of AI-based sequence and structural design technologies, innovations in formulations that enhance stability and delivery efficiency, and the expansion of therapeutic indications such as metabolic, immune, and fibrotic diseases. In particular, the development of orally available peptides, long-acting formulations, and tissue-targeted delivery technologies is greatly increasing the practicality and market potential of peptide therapeutics, opening new treatment paradigms.

It is also truly encouraging to see the growing participation from both academia and industry at our recent Symposium. From major global companies to venture firms, many are devoting tremendous effort to peptide-based drug development, underscoring the increasing importance of our Society. As we approach our 30th anniversary in 2027, our Society has now entered a stage of maturity, with nearly 300 participants each year, firmly establishing itself as the leading academic society in peptide and proteinx field.

Amid these rapid changes, our Society will continue to strengthen collaboration among academia, industry, and research institutes; foster the next generation of researchers; and expand platforms for sharing cutting-edge research and technological advances. In particular, we will work to reinforce academic exchange and cooperation with our close neighbors—Japan and China—through more active trilateral engagement.

I kindly ask for your continued participation and support, and I wish all of you good health and great success in your research endeavors.